Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study

By Aversa Antonio   Bruzziches Roberto   Francomano Davide   Greco Emanuela A.   Fornari Rachele   Luigi Luigi Di   Lenzi Andrea   Migliaccio Silvia  

The Aging Male, Vol. 15, Iss. 2, 2012-06 ,pp. : 96-102

Informa Healthcare

Access to resources Recommend Favorite

Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9-12 February 2006, Salzburg, Austria

By Morales A.   Nieschlag E.   Schubert M.   Yassin A. A.   Zitzmann M.   Oettel M.  

The Aging Male, Vol. 9, Iss. 4, 2006-12 ,pp. : 221-227

Informa Healthcare

Access to resources Recommend Favorite

Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study

By Bouloux Pierre M. G.  

The Aging Male, Vol. 16, Iss. 2, 2013-06 ,pp. : 38-47

Informa Healthcare

Access to resources Recommend Favorite

Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS)

By Kaplan Steven A.  

The Aging Male, Vol. 16, Iss. 2, 2013-06 ,pp. : 48-51

Informa Healthcare

Access to resources Recommend Favorite

Testosterone undecanoate: a review

By Lyngdorf Peter  

Aging Health, Vol. 8, Iss. 4, 2012-08 ,pp. : 341-349

Future Medicine

Access to resources Recommend Favorite